Should we use statins in all patients with chronic kidney disease without dialysis therapy? The current state of knowledge

2015 ◽  
Vol 47 (5) ◽  
pp. 805-813 ◽  
Author(s):  
Jacek Rysz ◽  
Anna Gluba-Brzózka ◽  
Maciej Banach ◽  
Andrzej Więcek
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Dialysis Therapy ◽  
Current State

Effect of parameters of renal replacement therapy on platelet aggregation activity

2020 ◽  
Author(s):  
Т.В. Марченко ◽  
А.В. Гончарова ◽  
И.Н. Соловьева ◽  
Е.О. Марченко ◽  
А.М. Исаева
Keyword(s):  
Chronic Kidney Disease ◽  
Platelet Aggregation ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Normal Range ◽  
Dialysis Therapy ◽  
Before And After ◽  
Aggregation Activity

Цель исследования: оценить влияние параметров заместительной почечной терапии (ЗПТ) на агрегационную активность тромбоцитов у пациентов с хронической болезнью почек (ХБН). Материалы и методы. Было выполнено 25 процедур гемодиализа (ГД) и 10 процедур гемодиафильтрации (ГДФ) 35 больным с ХБП. Изучали динамику агрегационной активности тромбоцитов до и после экстракорпоральных процедур. Результаты. После процедуры ГД агрегация тромбоцитов снижалась, а после процедуры ГДФ нарастала, не выходя за пределы нормальных значений. Параметры процедур ЗПТ на агрегацию тромбоцитов значимого влияния не оказывали. Заключение. Разовая процедура ЗПТ протяженностью не более 4 ч, проводимая с учетом всех современных требований к диализной терапии, не оказывает негативного влияния на функциональную активность тромбоцитов. Процедура ГДФ приводит к непринципиальному росту агрегационной активности тромбоцитов. Aim: to assess the effect of renal replacement therapy (RRT) parameters on platelet aggregation activity in patients with chronic kidney disease (CKD). Materials and methods. For 35 patients with CKD 25 hemodialysis (HD) procedures and 10 hemodiafiltration (HDF) procedures were performed. We studied the dynamics of platelet aggregation activity before and after extracorporeal procedures. Results. After the HD procedure, platelet aggregation decreased, and after the HDF procedure it increased, without going outside the normal range. Parameters of RRT procedures did not have a significant effect on platelet aggregation. Conclusion. A single RRT procedure not more than 4 hours with all nowadays requirements for dialysis therapy does not adversely affect the functional platelets activity. The HDF procedure leads to an unprincipled increasing of platelet aggregation activity.

Dialysis Therapy and Conservative Management of Advanced Chronic Kidney Disease in the Elderly: A Systematic Review

Nephron ◽  
2017 ◽  
Vol 137 (3) ◽  
pp. 178-189 ◽  
Author(s):  
Supakanya Wongrakpanich ◽  
Paweena Susantitaphong ◽  
Suramath Isaranuwatchai ◽  
Jirat Chenbhanich ◽  
Somchai Eiam-Ong ◽  
...  
Keyword(s):  
Systematic Review ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Conservative Management ◽  
The Elderly ◽  
Dialysis Therapy ◽  
Advanced Chronic Kidney Disease

scholarly journals Complications of chronic kidney disease: current state, knowledge gaps, and strategy for action

2017 ◽  
Vol 7 (2) ◽  
pp. 122-129 ◽  
Author(s):  
Aminu K. Bello ◽  
Mona Alrukhaimi ◽  
Gloria E. Ashuntantang ◽  
Shakti Basnet ◽  
Ricardo C. Rotter ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Knowledge Gaps ◽  
Current State

scholarly journals Approximation of Corrected Calcium Concentrations in Advanced Chronic Kidney Disease Patients with or without Dialysis Therapy

Nephron Extra ◽  
2015 ◽  
Vol 5 (2) ◽  
pp. 39-49 ◽  
Author(s):  
Yoshio Kaku ◽  
Susumu Ookawara ◽  
Haruhisa Miyazawa ◽  
Kiyonori Ito ◽  
Yuichiro Ueda ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Dialysis Therapy ◽  
Advanced Chronic Kidney Disease

Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy

2004 ◽  
Vol 44 (3) ◽  
pp. 455-465 ◽  
Author(s):  
Mohamed E. Suliman ◽  
Peter Stenvinkel ◽  
A. Rashid Qureshi ◽  
Peter Bárány ◽  
Olof Heimbürger ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Amino Acids ◽  
Kidney Disease ◽  
Free Amino Acids ◽  
Free Amino ◽  
Dialysis Therapy ◽  
Plasma Free Amino Acids

scholarly journals Glycoinsulinemic parameters associated with vitamin D status in patients with chronic kidney disease undergoing dialysis therapy

2021 ◽  
Vol 48 (4) ◽  
pp. 534-544
Author(s):  
Camila Santos-Marreiro ◽  
Thaís Rodrigues-Nogueira ◽  
Débora Cavalcante-Braz ◽  
Paulo Pedro do-Nascimento ◽  
Suzana Maria Rebelo Sampaio da-Paz ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Vitamin D ◽  
Kidney Disease ◽  
Vitamin D Status ◽  
Dialysis Therapy

scholarly journals Canadian Senior Renal Leaders Community of Practice: Vulnerable Populations With Chronic Kidney Disease—Evidence to Inform Policy

2020 ◽  
Vol 7 ◽  
pp. 205435812093097
Author(s):  
Rachael Erdmann ◽  
Louise Morrin ◽  
Rebecca Harvey ◽  
Lisa Joya ◽  
Amy Clifford ◽  
...  
Keyword(s):  
United States ◽  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Disease Management ◽  
Community Of Practice ◽  
Vulnerable Populations ◽  
Web Sites ◽  
Literature Search ◽  
The United States ◽  
Current State

Purpose: Low socioeconomic status, race, ethnicity, and rural/remote populations are all associated with disparities in access, care, and outcomes for chronic kidney disease (CKD). There have been different interventions supported by Canadian renal programs to address these disparities. This article reviews the evidence for impact of strategies to reduce inequities experienced by vulnerable populations living with or at risk of CKD and to collate and share interprovincial targeted interventions through the newly formed “Canadian Senior Renal Leaders Community of Practice” focused on translating evidence into clinical practice and policy. Source of Information: A literature search of Medline, CINAHL, PubMed, and Google Scholar from 2008 to 2018 identified 13 reports of processes and interventions that have been implemented in Australia, Canada, and the United States to reduce inequities in CKD care and can be categorized into 3 broad areas: (1) early screening and prevention, (2) disease management and dialysis, and (3) pretransplant. Web sites from each Canadian jurisdiction and from Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD) Network were used to assess the current state of Canadian initiatives. Methods: Reviews were completed to gather information on renal initiatives for vulnerable populations, including (1) identification of populations that experience disparities in access to care or in outcomes in the context of CKD prevention and treatment and (2) interventions that have been implemented to reduce disparities in access, care, and outcomes for vulnerable populations with CKD. A current state summary of Canadian initiatives related to vulnerable populations was conducted through a review of publicly available information, including a review of renal program Web sites and a review of current projects related to vulnerable populations that are part of Can-SOLVE CKD. Can-SOLVE CKD is a Canadian Institutes of Health Research Strategy for Patient-Oriented Research (CIHR-SPOR) funded research network to transform the care of people affected by kidney disease. Key Findings: Interventions to improve inequities in access to CKD screening, disease management, and care are successful when developed with community engagement, provided to the patient in their own environment, and tailored to specific populations. Many provincial renal programs have implemented initiatives to support vulnerable populations with or at risk of CKD. Current projects funded through CIHR SPOR focus on underserved populations and involve partnerships with Indigenous populations. Many renal programs in Canada had or were in the process of implementing interventions to support vulnerable populations with CKD; however, information about the initiatives were not readily available online despite a strong interest and opportunity to support interprovincial knowledge sharing. Despite this common interest, little information is systematically shared between Canadian jurisdictions to support interprovincial sharing to promote evidence-informed policy and program development. Efforts will be made through the newly formed Canadian Senior Renal Leaders Community of Practice to collaborate and share learnings to inform future program and policy development, implementation, and evaluation. Limitations: As this was not a systematic review, literature search only encompassed studies published in English between 2008 and 2018. It is possible that populations and interventions were overlooked during the search and through the screening process. Furthermore, the controversial definition of “vulnerable” and literature that only came from Canada, the United States, and Australia limits the generalizability of this review.

scholarly journals NT-proBNP in the Prognosis of Death or Need for Renal Replacement Therapy in Patients with Stage 3–5 Chronic Kidney Disease

2019 ◽  
Vol 9 (2) ◽  
pp. 125-134
Author(s):  
Leszek Gromadziński ◽  
Beata Januszko-Giergielewicz ◽  
Kamila Czarnacka ◽  
Piotr Pruszczyk
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Independent Predictor ◽  
Characteristic Curve ◽  
Multivariate Regression Analysis ◽  
Dialysis Therapy ◽  
Cutoff Value ◽  
Initiation Of Dialysis

Background: The risk of cardiovascular (CV) complications is much greater in patients with chronic kidney disease (CKD). The aim of this study was to assess predictors of mortality, renal failure progression, and the need for dialysis in patients with CKD. Methods: The study group consisted of 70 patients with stage 3–5 CKD, followed up on average for 33.4 ± 15.6 months. Laboratory tests and echocardiography were performed on all patients. Composite endpoints were defined as (1) all-cause mortality and (2) mortality or renal replacement therapy (RRT), defined as the initiation of dialysis therapy. Results: During the observation period, 13 patients died and 11 began dialysis therapy. NT-proBNP was found to be a significant predictor in receiver operating characteristic curve analysis for all study endpoints. The optimal cutoff value for NT-proBNP as a predictor of mortality was 569.8 pg/mL, with a sensitivity of 53.8% and a specificity of 89.1%. For mortality or RRT, the cutoff value for NT-proBNP was 384.9 pg/mL, with a sensitivity and specificity of 70.8 and 72.7%, respectively. In a multivariate regression analysis, NT-proBNP was an independent predictor of mortality with an OR = 7.5 (95% CI: 1.05–53.87; p = 0.044) and of mortality or RRT with an OR = 4.7 (95% CI: 1.01–22.66; p = 0.048). Conclusions: NT-proBNP is an independent predictor of mortality in patients with CKD and can also be useful for CV risk stratification in this patient population.

scholarly journals Obesity and Post-Transplant Diabetes Mellitus in Kidney Transplantation

2021 ◽  
Vol 10 (11) ◽  
pp. 2497
Author(s):  
Paloma Leticia Martin-Moreno ◽  
Ho-Sik Shin ◽  
Anil Chandraker
Keyword(s):  
Diabetes Mellitus ◽  
Chronic Kidney Disease ◽  
Weight Loss ◽  
Kidney Transplantation ◽  
Kidney Disease ◽  
Post Transplant ◽  
Transplant Patients ◽  
Current State ◽  
Immunosuppressive Medications ◽  
Before And After

Worldwide, the prevalence obesity, diabetes, and chronic kidney disease is increasing apace. The relationship between obesity and chronic kidney disease is multidimensional, especially when diabetes is also considered. The optimal treatment of patients with chronic kidney disease includes the need to consider weight loss as part of the treatment. The exact relationship between obesity and kidney function before and after transplantation is not as clear as previously imagined. Historically, patients with obesity had worse outcomes following kidney transplantation and weight loss before surgery was encouraged. However, recent studies have found less of a correlation between obesity and transplant outcomes. Transplantation itself is also a risk factor for developing diabetes, a condition known as post-transplant diabetes mellitus, and is related to the use of immunosuppressive medications and weight gain following transplantation. Newer classes of anti-diabetic medications, namely SGLT-2 inhibitors and GLP-1 agonists, are increasingly being recognized, not only for their ability to control diabetes, but also for their cardio and renoprotective effects. This article reviews the current state of knowledge on the management of obesity and post-transplant diabetes mellitus for kidney transplant patients.

Sign in / Sign up

Export Citation Format

Share Document